Rizafilm is a drug owned by Gensco Laboratories Llc Dba Gensco Pharma. It is protected by 1 US drug patent filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 30, 2034. Details of Rizafilm's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US9301948 | Instantly wettable oral film dosage form without surfactant or polyalcohol |
Jul, 2034
(9 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Rizafilm's patents.
Latest Legal Activities on Rizafilm's Patents
Given below is the list of recent legal activities going on the following patents of Rizafilm.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 05 Oct, 2023 | US9301948 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 23 Sep, 2019 | US9301948 |
| Patent Issue Date Used in PTA Calculation Critical | 05 Apr, 2016 | US9301948 |
| Recordation of Patent Grant Mailed Critical | 05 Apr, 2016 | US9301948 |
| Email Notification Critical | 17 Mar, 2016 | US9301948 |
| Issue Notification Mailed Critical | 16 Mar, 2016 | US9301948 |
| Application Is Considered Ready for Issue Critical | 03 Mar, 2016 | US9301948 |
| Dispatch to FDC | 03 Mar, 2016 | US9301948 |
| Issue Fee Payment Verified Critical | 01 Mar, 2016 | US9301948 |
| Issue Fee Payment Received Critical | 01 Mar, 2016 | US9301948 |
US patents provide insights into the exclusivity only within the United States, but Rizafilm is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Rizafilm's family patents as well as insights into ongoing legal events on those patents.
Rizafilm's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Rizafilm's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 30, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Rizafilm Generic API suppliers:
Rizatriptan Benzoate is the generic name for the brand Rizafilm. 17 different companies have already filed for the generic of Rizafilm, with Unichem having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Rizafilm's generic
Alternative Brands for Rizafilm
Rizafilm which is used for treating high blood pressure and heart failure., has several other brand drugs using the same active ingredient (Rizatriptan Benzoate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Organon |
| |
| Organon Llc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Rizatriptan Benzoate, Rizafilm's active ingredient. Check the complete list of approved generic manufacturers for Rizafilm
About Rizafilm
Rizafilm is a drug owned by Gensco Laboratories Llc Dba Gensco Pharma. It is used for treating high blood pressure and heart failure. Rizafilm uses Rizatriptan Benzoate as an active ingredient. Rizafilm was launched by Gensco in 2023.
Approval Date:
Rizafilm was approved by FDA for market use on 14 April, 2023.
Active Ingredient:
Rizafilm uses Rizatriptan Benzoate as the active ingredient. Check out other Drugs and Companies using Rizatriptan Benzoate ingredient
Treatment:
Rizafilm is used for treating high blood pressure and heart failure.
Dosage:
Rizafilm is available in film form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 10MG BASE | FILM | Discontinued | ORAL |